College of Basic Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
Molecular Research in Traditional Chinese Medicine Group, Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology & Immunology, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Evid Based Complement Alternat Med. 2015;2015:428106. doi: 10.1155/2015/428106. Epub 2015 Oct 18.
We investigated the effect of Jiangya Tongluo (JYTL) formula on renal function in rats with hypertensive nephrosclerosis. A total of 21 spontaneously hypertensive rats (SHRs) were randomized into 3 groups: valsartan (10 mg/kg/d valsartan), JYTL (14.2 g/kg/d JYTL), and a model group (5 mL/kg/d distilled water); Wistar Kyoto rats comprised the control group (n = 7, 5 mL/kg/d distilled water). Treatments were administered by gavage every day for 8 weeks. Blood pressure, 24-h urine protein, pathological changes in the kidney, serum creatinine, and blood urea nitrogen (BUN) levels were estimated. The contents of adrenomedullin (ADM) and angiotensin II (Ang II) in both the kidney and plasma were evaluated. JYTL lowered BP, 24-h urine protein, serum creatinine, and BUN. ADM content in kidneys increased and negatively correlated with BP, while Ang II decreased and negatively correlated with ADM, but there was no statistically significant difference of plasma ADM between the model and the treatment groups. Possibly, activated intrarenal renin-angiotensin system (RAS) plays an important role in hypertensive nephrosclerosis and the protective function of ADM via local paracrine. JYTL may upregulate endogenous ADM level in the kidneys and antagonize Ang II during vascular injury by dilating renal blood vessels.
我们研究了降压通络方对高血压肾硬化大鼠肾功能的影响。将 21 只自发性高血压大鼠(SHRs)随机分为 3 组:缬沙坦(10mg/kg/d 缬沙坦)、降压通络方(14.2g/kg/d 降压通络方)和模型组(5ml/kg/d 蒸馏水);Wistar 京都大鼠为对照组(n=7,5ml/kg/d 蒸馏水)。每天灌胃给药,持续 8 周。评估血压、24 小时尿蛋白、肾脏病理变化、血清肌酐和血尿素氮(BUN)水平。评估肾脏和血浆中肾上腺髓质素(ADM)和血管紧张素 II(Ang II)的含量。降压通络方可降低血压、24 小时尿蛋白、血清肌酐和 BUN。肾脏中 ADM 含量增加,与血压呈负相关,而 Ang II 减少,与 ADM 呈负相关,但模型组和治疗组之间血浆 ADM 无统计学差异。可能是激活的肾内肾素-血管紧张素系统(RAS)在高血压肾硬化中起重要作用,ADM 通过局部旁分泌发挥保护作用。降压通络方可能通过扩张肾血管增加肾脏内源性 ADM 水平,并拮抗血管损伤时的 Ang II。